Objective To explore the application of Chinese Drug-Related Problems Classification System in the pharmaceutical care of inpatients in neurology department.Methods A total of 222 inpatients admitted to the Department of Neurology of Affiliated Jinhua Hospital,Zhejiang University School of Medicine from March to June 2022 were selected as the study subjects,and the work records of clinical pharmacists were retrospectively analyzed.The drug-related problems(DRP)were sorted and analyzed according to the Chinese Drug-Related Problems Classification System.Binomial Logistic regression model was used to analyse the influencing factors of DRP.Results Among the 222 patients,76(34.23%)had DRP and a total of 104 DRP were found.The main problem type of DRP was treatment safety(39.42%).The involving objects of DRP were all doctors.In the severity assessment,the most involved level was"DRP reached the patient,but the patient was not harmed"(81.73%).The main reason for DRP was"choice of drugs"(67.31%),followed by"usage and dosage"(26.92%).A total of 62(59.62%)DRP intervention schemes were accepted,and the overall acceptance rate of intervention schemes was 87.32%.In the end,61(58.65%)DRPs were resolved.The drug class with the largest number of DRP cases was antiplatelet drugs.Binomial Logistic regression analysis showed that the number of drug varieties[OR=1.097,95%CI(1.030,1.167)]was the influencing factor for the occurrence of DRP in neurology inpatients(P<0.05).Conclusion DRP is common in inpatients of neurology department.Chinese Drug-Related Problems Classification System is helpful for clinical pharmacists to review and sort pharmaceutical care data,summarize common problems and solving experience,and improve the effect of pharmaceutical care.

Antibodies, Antinuclear ; Autoantibodies ; China ; Cohort Studies ; Humans ; Scleroderma, Systemic

Objective:To study the effect of pidotimod combined with montelukast sodium in the treatment of patients with asthma, and its influence on the levels of inflammatory factors and immune function.Methods:From February 2019 to February 2020, 102 patients with bronchial asthma admitted to Zhuji People's Hospital were randomly divided into the observation group and the control group, with 51 cases in each group.The control group was treated with montelukast sodium, and the observation group was given pidotimod combined with montelukast sodium.The clinical effect, lung function index, inflammatory factors, T lymphocyte subsets and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 90.20%(46/51), which was higher than that of the control group [74.51%(38/51)](χ 2=4.317, P=0.038). After treatment, FEV 1, FVC, PEF in the observation group were (82.89±6.94)%, (3.89±0.45)L, (3.49±0.49)L/s, respectively, which were higher than those in the control group [(77.89±6.79)%, (3.58±0.43)L, (3.21±0.45)L/s] ( t=7.370, 5.753, 4.239, all P<0.05). After treatment, the serum levels of procalcitonin (PCT), interleukin-6 (IL-6), C-reactive protein (CRP) in the observation group were (1.45±0.49)μg/L, (9.87±2.65)mg/L, (5.79±1.48)mg/L, respectively, which were lower than those in the control group [(1.79±0.55)μg/L, (12.34±2.97)mg/L, (7.23±1.68)mg/L] ( t=4.624, 6.542, 8.090, all P<0.05). After treatment, the CD 3+ , CD 4+ , CD 4+ /CD 8+ in the observation group were (53.43±5.43)%, (46.34±5.31)%, (1.54±0.23), respectively, which were higher than those in the control group [(48.09±5.17)%, (41.89±5.15)%, (1.26±0.22)], while the CD 8+ in the observation group[(30.65±3.54)%] was lower than that in the control group[(33.72±3.69)%], the differences were statistically significant ( t=3.901, 4.080, 4.072, 5.967, all P<0.05). During the treatment period, the incidences of adverse reactions in the observation group and the control group were 15.69%(8/51) and 9.80%(5/51), respectively, there was no statistically significant difference between the two groups (χ 2=0.793, P=0.373). Conclusion:Pidotimod combined with montelukast sodium has significant therapeutic effect on bronchial asthma.It can improve the pulmonary function, reduce the levels of inflammatory factors, improve the immune function of the body, and has good therapeutic safety.It has a high clinical application value.

ATP-Binding Cassette Transporters ; genetics ; DNA Copy Number Variations ; genetics ; Genetic Predisposition to Disease ; Gout ; genetics ; Humans ; Receptors, IgG ; genetics ; Receptors, Interleukin-17 ; genetics

Objective To evaluate the efficacy and safety of aripiprazole treatment for co-morbid attention defi?ciency hyperactivity disorder (ADHD) in children with Tourette syndrome (TS). Methods Forty four TS children with co-morbid ADHD were randomly divided into aripiprazole group and haloperidol group. The aripiprazole group and halo?peridol group received aripiprazole and haloperidol treatment for 12 weeks, respectively. Yale global tic severity scale (YGTSS) and Conners parent symptom questionnaire (PSQ) were used to assess the tic and ADHD symptoms before, 2, 4, 8 and 12 weeks after treatment. Side effects were recorded weekly. Results Repeated measure ANOVA indicated that the main effects of groups was not significant to the YGTSS scores (P>0.05), but significant to the PSQ scores (P<0.05). After 12-week treatment, the YGTSS scores between two groups were not significantly different (P>0.05). The PSQ scores of aripiprazole group were significantly lower than that of haloperidol group. The adverse reactions of aripiprazole group were milder compared with the haloperidol group (P<0.05). Conclusions The present study demonstrates that aripipra?zole has the same efficacy in the treatment of tics as haloperidol, improves co-morbid ADHD symptoms, and its adverse reactions are much less compared with haloperidol.

Objective To explore the influence of Montelukast in the treatment of patients with bronchial asthma on the immune response,and to provide the basis for clinical treatment.Methods 104 patients with bronchial asthma were selected.They were randomly divided into the treatment group and the control group by the random number table method,with 52 cases in each group.The control group patients were given conventional treatment,and the treatment group were treated with Montelukast on the basis of the control group.Daytime symptom and night symptom of the two groups before and after treatment were assessed,and airway reactivity by the early respiratory resistance (Rrsc)and response threshold (Dmin)were evaluated.And the change of T lymphocyte subsets before and after the treatment were detected.Results The day symptom scores,night symptom scores and Rrsc of the treatment group after treatment were respectively (0.49 ±0.12)points,(0.66 ±0.20)points and (2.19 ±0.38)cmH2 O,which were lower than those of the control group after treatment(t =7.90,8.13,8.24,all P <0.05).The data of the two groups after treatment were lower than those before treatment,the differences were statistically significant (t =9.38,8.66, 9.17,9.41,8.90,9.24,all P <0.05).Dmin of the treatment group after treatment was (8.29 ±0.44)U,which was higher than that of the control group after treatment,the data of the two groups after treatment were higher than those before the treatment,the differences were statistically significant(t =7.41,8.23,all P <0.05).CD +4 and CD +4 /CD +8 of the treatment group after treatment were (43.03 ±5.02)% and(1.79 ±0.34),respectively,which were higher than those of the control group after treatment (t =9.81,10.04,all P <0.05 ).The data of the two groups after treatment were higher than those before the treatment,the differences were statistically significantly different (t =10.62,10.33,10.93,10.62,all P <0.05).CD +8 of the treatment group after treatment was (23.38 ±3.88)%, which was lower than that of the control group after treatment(t =9.93,P <0.05),the data of the two groups after treatment were lower than those before treatment,the differences were statistically significant (t =9.16,9.29,all P <0.05 ).Conclusion Montelukast treatment of bronchial asthma can significantly improve symptoms and immune function of patients,it is worthy of clinical popularization and application.

China Partner Network (CPN) training project would train professionals for better management of children rehabilitation, including advanced theory and manipulation in treatment and functional assessment of children with cerebral palsy, psychological education,and orthotics as well as operation and non-operation protocols. Domestic status quo in this area and some other relevant experiences were also compared with CPN.

Dyskinetic cerebral palsy is the general type of cerebral palsy. This review discussed the pathogenesis, functional disorders,assessment and rehabilitation for it in the past years.

Objective To investigate the current status of family rehabilitation for children with disability and the unmet needs of habilitation/rehabilitation for their parents. Methods Family Rehabilitation Needs Survey Questionnaire was used to investigate 186 families of the children with disability from 5 rehabilitation institutions in 4 provinces. Results Most families accepted family rehabilitation, including family support, developed rehabilitation scheme, telephone counseling, real-time guidance and appointment for family rehabilitation. Most families would spent 1-2 hours a day for the family rehabilitation, and prefer the rehabilitation of gross motion. However, the rehabilitation agencies played less importance on supports of family rehabilitation. Conclusion The family rehabilitation supports needs to be improved in specification of rehabilitation process, developing rehabilitation scheme and quality control.

Objective To apply the theory and model of International Classification of Functioning, Disability and Health (Children and Youth Version) (ICF-CY) in rehabilitation for children with cerebral palsy. Methods A case accepted rehabilitation in the framework of ICF-CY was reported. Results and Conclusion The framework of ICF-CY can be used in rehabilitation for children with cerebral palsy.